CN109893646A - A kind of composition for treating depression - Google Patents
A kind of composition for treating depression Download PDFInfo
- Publication number
- CN109893646A CN109893646A CN201910209432.6A CN201910209432A CN109893646A CN 109893646 A CN109893646 A CN 109893646A CN 201910209432 A CN201910209432 A CN 201910209432A CN 109893646 A CN109893646 A CN 109893646A
- Authority
- CN
- China
- Prior art keywords
- composition
- depression
- treating depression
- gonadorelin
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to a kind of composition for treating depression and its application, the composition is prepared by Gonadorelin, Radix Glycyrrhizae, radix bupleuri and semen ziziphi spinosae.Compared with the common antidepressant Prozac of clinic, the present composition can improve behavior depression, and faster, more comprehensively.
Description
Technical field
The invention belongs to field of medicaments, and in particular to a kind of composition, in particular to a kind of composition for treating depression
And its application.
Background technique
Depression can be caused by a variety of causes, low for main clinical characteristics with significant and lasting mental state.Typical table
Now include three movable reductions of dimension: depressed, retardation of thinking, bulesis decline, certain patients are with somatization table
Based on existing.The disease incidence of depression is in rising trend in recent years, it is contemplated that arrives the year two thousand twenty, depression is by the fourth-largest disease in the ranking world
Suffer from, becomes the second largest disease for being only second to coronary heart disease.Depression is also disabling condition, and serious person can cause to commit suiside, and gives house
Front yard and society bring heavy financial burden.
Though the curative effect of clinical antidepressant medicine is worth affirmative at present, generally existing drug effect is weak, works slow, action time
Short, the disadvantages of adverse reaction is obvious.Currently, clinically the antidepressants of a line mainly include the suppression of selective serotonin reuptake
Preparation, serotonin and norepinephrine reuptake inhibitors etc., but it is slow using this kind of drug effect, and effect is narrow, after drug withdrawal
It is easy to recur.Currently, entire industry is all researching and developing quick, Small side effects, more efficiently therapeutic agent.In Europe, Englishman
It is annual to take 8,600,000,000 pounds because for the treatment of depression；In the U.S., depression gives loss caused by economy to reach 53,000,000,000 every year
Dollar；And in China, incidence of depression has also reached 5 ~ 6%, annual about 30,000,000,000 RMB for the treatment of depression expense.But
It is to be influenced by traditional concept and economic pressures, at present in the patients with depression in China, only 10% or so crowd can be actively
Ground carries out medicine and drug therapy.Therefore, when selecting drug therapy depression, the curative effect and safety of drug to be not only particular about
Property, more to consider the economy and applicability of drug, save treatment cost.With regard to complicated and changeable, patient compliance of depressive symptom
For the adverse reaction of property and drug, traditional Chinese medicine shows unique advantage for the treatment of depression, and is increasingly becoming research
Hot spot.
Researches show that the expression that the reduction of neurotrophic factor (BDNF) level changes BDNF is related with the disturbance of emotion
Gene potentially contributes to the development symptom for improving depression.Because GnRH nerve synapse passes through forebrain in its growth course
Region rich in BDNF carries out, therefore it has been proposed that brain-derived neurotrophic factor (BDNF) and GnRH nerve synapse to outgrowth
With certain relationship.GnRH (Gonadorelin) is artificial synthesized decapeptide proteohormone, itself has and improves anterior pituitary
Sensibility of the gonadotroph to GnRH.
The present inventor warp experimental studies have found that, Gonadorelin, Radix Glycyrrhizae, radix bupleuri and semen ziziphi spinosae preparation composition tool
There is antidepressant effect.It is had not been reported in document at present and treats depression, and Central nervous system accordingly with the composition
Correlative study in terms of disease treatment.
Summary of the invention
The present invention provides a kind of pharmaceutical composition for treating depression, which is characterized in that the composition mainly by dagger-axe that
Rayleigh, Radix Glycyrrhizae, radix bupleuri and semen ziziphi spinosae are prepared for effective component.
A kind of composition for treating depression, which is characterized in that the weight of each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 150g ~ 350g；
Radix Glycyrrhizae 60g ~ 200g；
Radix bupleuri 30g ~ 100g；
Gonadorelin 0.02g ~ 0.07g.
In section Example, the weight of each effective component of the composition is constituted are as follows:
Semen ziziphi spinosae 120g ~ 320g；
Radix Glycyrrhizae 80g ~ 180g；
Radix bupleuri 50g ~ 90g；
Gonadorelin 0.03g ~ 0.05g.
The invention also discloses a kind of preparation methods of above-mentioned composition for treating depression, comprising the following steps:
Radix Glycyrrhizae, radix bupleuri and semen ziziphi spinosae processing: it takes each component to be decocted, filter, being concentrated to get concentrate, then by concentrate 60
DEG C ~ 100 DEG C under the conditions of be dried, be then crushed to 200 mesh extract powder derived above；Extract powder is mixed with Gonadorelin
It is even.
A kind of composition for treating depression, the drug are oral preparation.
The drug is oral preparation, which is characterized in that the preparation is selected from oral solutions, tablet, capsule or particle
Agent.
In specific embodiment, the oral preparation is oral solutions.
Application of the composition in preparation medicament for treatment of depression.
A kind of drug for treating depression, which is characterized in that the composition also includes pharmaceutically acceptable auxiliary
Material.
Compared with prior art, the present invention provides a kind of new compositions for being used to treat depression.Experiment display dagger-axe
The composition that Rayleigh, Radix Glycyrrhizae, radix bupleuri and semen ziziphi spinosae are prepared can improve the behavior of lipopolysaccharides depression mouse morbid state sample, pleasant sensation lacks
The behavior depressions such as mistake, behavioral despair.Compared with the common antidepressant of clinic, the composition pretreatment is small to lipopolysaccharides depression
Mouse behavior depression improves faster, more comprehensively.
Specific embodiment
The present invention is described in further details combined with specific embodiments below, but embodiment should not limit as to protection model
The limitation enclosed.
Embodiment 1
The weight of a kind of composition for treating depression, each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 150g；
Radix Glycyrrhizae 60g；
Radix bupleuri 30g；
Gonadorelin 0.02g.
Each component is decocted, is filtered, being concentrated to get concentrate, then concentrate is dried under the conditions of 80 DEG C, with
After be crushed to 200 mesh extract powder derived above.Extract powder is uniformly mixed with Gonadorelin, sodium sulfite is added and water is prepared into
To oral solutions.
Embodiment 2
The weight of a kind of composition for treating depression, each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 280g；
Radix Glycyrrhizae 100g；
Radix bupleuri 70g；
Gonadorelin 0.05g.
Each component is decocted, is filtered, being concentrated to get concentrate, then concentrate is dried under the conditions of 90 DEG C, with
After be crushed to 200 mesh extract powder derived above.Extract powder is uniformly mixed with Gonadorelin, sodium sulfite is added and water is prepared into
To oral solutions.
Embodiment 3
The weight of a kind of composition for treating depression, each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 320g；
Radix Glycyrrhizae 180g；
Radix bupleuri 95g；
Gonadorelin 0.07g.
Each component is decocted, is filtered, being concentrated to get concentrate, then concentrate is dried under the conditions of 80 DEG C, with
After be crushed to 200 mesh extract powder derived above.Extract powder is uniformly mixed with Gonadorelin, sodium sulfite is added and water is prepared into
To oral solutions.
Embodiment 4
The weight of a kind of composition for treating depression, each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 150g；
Radix Glycyrrhizae 60g；
Radix bupleuri 30g；
Gonadorelin 0.02g.
Each component is decocted, is filtered, being concentrated to get concentrate, then concentrate is dried under the conditions of 70 DEG C, with
After be crushed to 200 mesh extract powder derived above.Extract powder is uniformly mixed with Gonadorelin, is mixed and made into capsule with glucose
Agent.
Embodiment 5
The weight of a kind of composition for treating depression, each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 280g；
Radix Glycyrrhizae 100g；
Radix bupleuri 70g；
Gonadorelin 0.05g.
Each component is decocted, is filtered, being concentrated to get concentrate, then concentrate is dried under the conditions of 70 DEG C, with
After be crushed to 200 mesh extract powder derived above.Extract powder is uniformly mixed with Gonadorelin, is mixed and made into capsule with glucose
Agent.
Embodiment 6
The weight of a kind of composition for treating depression, each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 320g；
Radix Glycyrrhizae 180g；
Radix bupleuri 95g；
Gonadorelin 0.07g.
Each component is decocted, is filtered, being concentrated to get concentrate, then concentrate is dried under the conditions of 70 DEG C, with
After be crushed to 200 mesh extract powder derived above.Extract powder is uniformly mixed with Gonadorelin, is mixed and made into capsule with glucose
Agent.
Embodiment 7
The weight of a kind of composition for treating depression, each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 150g；
Radix Glycyrrhizae 60g；
Radix bupleuri 30g；
Gonadorelin 0.02g.
Each component is decocted, is filtered, being concentrated to get concentrate, then concentrate is dried under the conditions of 60 DEG C, with
After be crushed to 200 mesh extract powder derived above.Extract powder is uniformly mixed with Gonadorelin, is mixed and made into particle punching with starch
Agent.
Embodiment 8
The weight of a kind of composition for treating depression, each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 280g；
Radix Glycyrrhizae 100g；
Radix bupleuri 70g；
Gonadorelin 0.05g.
Each component is decocted, is filtered, being concentrated to get concentrate, then concentrate is dried under the conditions of 60 DEG C, with
After be crushed to 200 mesh extract powder derived above.Extract powder is uniformly mixed with Gonadorelin, is mixed and made into particle punching with starch
Agent.
Embodiment 9
The weight of a kind of composition for treating depression, each effective component of composition is constituted are as follows:
Semen ziziphi spinosae 320g；
Radix Glycyrrhizae 180g；
Radix bupleuri 95g；
Gonadorelin 0.07g.
Each component is decocted, is filtered, being concentrated to get concentrate, then concentrate is dried under the conditions of 60 DEG C, with
After be crushed to 200 mesh extract powder derived above.Extract powder is uniformly mixed with Gonadorelin, is mixed and made into particle punching with starch
Agent.
Embodiment 10
Choose adult healthy cleaning grade male mouse of kunming, weight 25-32g.All mouse raisings are in 20 ~ 24 DEG C of room temperature, relatively
Humidity 50 ~ 60%, 12h daily cycle, free water and feed.Adaptive feeding 1 week (8/cage), then single cage raising carried out
Experiment.
Experiment mice is randomly divided into control group, model group, example 1 group, 2 groups of embodiment, 3 groups of embodiment and Prozac
Group, every group 8.Control group and isometric sterile saline is injected intraperitoneally in model group the 1st day to the 4th day, once a day.Model
Group: on day 4 after injecting normal saline, intraperitoneal injection of LPS (0.5mg/kg) establishes depression model；Prozac group: the 4th
Before its injection lipopolysaccharides (0.5mg/kg), stomach-filling Prozac (1mg/kg), once a day；Example 1 group, 2 groups of embodiment, reality
Apply 3 groups of example: injecting LPS(0.5mg/kg on day 4) before, difference gastric infusion example 1 group, 2 groups of embodiment, embodiment 3
The preparation 200mg/kg of group, once a day.Terminate to carry out behaviouristics detection afterwards for 24 hours in last dose.
The experiment of syrup preference, the experiment of spray sugar, spacious field experiment, forced swim test are carried out to mouse.The experiment of syrup preference can
To objectively respond the performance of depression animal anhedonia.Give 1% sucrose water 48h(of mouse adaptability drink before modeling and deprive pure water)；
Give mouse measures the two bottles of water (being 1% sucrose water and pure water respectively) set in advance simultaneously for modeling, inclined to prevent animal from generating position
Love, the position that 12h exchanges two water bottles is primary, records the quality that mouse in for 24 hours actively absorbs pure water and syrup.Syrup preference percentage
Than=(syrup consumes quality/(syrup consumes quality+pure water and consumes quality)) × 100%.
Spray sugar experiment is that reflection the another of animal anhedonia symptom predominantly detects mode.When detection, 10% sugarcane is uniformly sprayed
The behavior of mouse in 5min is observed and shot with video-corder to syrup in back of mice, and mouse, which licks, after being completed, in record 5min stings back
Accumulative lick stings the time.
Spacious field experiment is the classical Behaviors survey for detecting spontaneous activity in mice behavior.Experimental provision is with open-topped
Cuboid carton, bottom are 80cm × 80cm, high 40cm, are divided into 25 grids in bottom with marking pen, intermediate 9 grids become
Center lattice, mouse can move freely in the case.Before detection, mouse is made to adapt to quiet half-light environment 30min in advance, it, will be small when experiment
Mouse is placed in the same direction in the most central grid in spacious field bottom portion, is allowed it to stay in and is move freely 5min in carton, carries out simultaneously
Video recording；The total grid number of spacious field and evaluation mouse mobility are passed through to observe and record mouse afterwards.Passing through grid should be with animal
No less than 3 across the grid discrepancy of foot are standard.Before testing to next mouse, 75% alcohol wipe device case need to be used, then with dry
Dry towel avoids the interference of animal scent and excreta to experimental result in experimental provision.
Forced swim test is the Classic Experiments for reflecting depression animal behavior despair.Mouse is put into diameter about 12cm,
In the transparent glass cylinder of high about 25cm, depth of water 15cm in cylinder, water temperature is 21 ~ 25 DEG C.Mouse swimming behavior is shot with video camera
6min, and record accumulative dead time of the mouse in rear 4min.Motionless state refers to that animal has slightly in floating or four limbs
State of the stroke to keep head to emerge.
The results are shown in Table 1, and compared to the control group, model group mouse syrup perrcentage depletion is remarkably decreased (P < 0.05), licks
The sugared time substantially reduces (P < 0.05)；Compared with model group, each embodiment group mouse shows syrup perrcentage depletion and obviously rises
High (P< 0.05), lick the sugared time dramatically increase (P< 0.05)；Compared with model group, Prozac group and the performance of each embodiment group mouse
Out syrup perrcentage depletion no significant difference (P> 0.05), lick the sugared time dramatically increase (P< 0.05)；Compared with the control group, model
Group, each embodiment group and Prozac pretreated group mouse passed through in spacious field device total grid number substantially reduce (P< 0.05)；
Compared to model group, each embodiment group and Prozac group mouse pass through total grid number center lattice cumulative time no significant difference (P>
0.05)；Forced swim test data show that compared with the control group, the model group mouse forced swimming test dead time significantly extends about
(P< 0.05)；Each embodiment group and Prozac pretreatment can respectively significantly shorten the depression model mouse forced swimming test dead time (P
< 0.05).
1 each group experimental result of table
Note: compared with the control group,* P<0.05；Compared with model group,# P<0.05。
In summary Behaviors survey testing result is it is found that composition of the invention can improve lipopolysaccharides depression mouse morbid state
The behavior depressions such as sample behavior, anhedonia, behavioral despair.Compared with the common antidepressant Prozac of clinic, the composition
Pretreatment improves faster, more comprehensively lipopolysaccharides depression mouse behavior depression.
The above description of the embodiment is only used to help understand the method for the present invention and its core ideas, should not be construed as pair
Limitation of the invention.
The present invention relates to a kind of composition for treating depression and its applications, and the composition is by Gonadorelin, Radix Glycyrrhizae, radix bupleuri
It is prepared with semen ziziphi spinosae.Compared with the common antidepressant Prozac of clinic, the present composition can improve behavior depression,
And faster, more comprehensively.
Claims (8)
1. a kind of composition for treating depression, which is characterized in that the composition mainly by Gonadorelin, Radix Glycyrrhizae, radix bupleuri and
Semen ziziphi spinosae is prepared for effective component.
2. a kind of composition for treating depression as described in claim 1, which is characterized in that each effective component of composition
Weight is constituted are as follows:
Semen ziziphi spinosae 150g ~ 350g；
Radix Glycyrrhizae 60g ~ 200g；
Radix bupleuri 30g ~ 100g；
Gonadorelin 0.02g ~ 0.07g.
3. a kind of composition for treating depression as described in claim 1, which is characterized in that each effective component of the composition
Weight constitute are as follows:
Semen ziziphi spinosae 120g ~ 320g；
Radix Glycyrrhizae 80g ~ 180g；
Radix bupleuri 50g ~ 90g；
Gonadorelin 0.03g ~ 0.05g.
4. a kind of composition for treating depression as described in claim 1, which is characterized in that the composition is oral preparation.
5. a kind of composition for treating depression as claimed in claim 4, which is characterized in that the preparation is selected from oral solution
Agent, tablet, capsule or granule.
6. a kind of composition for treating depression as claimed in claim 5, which is characterized in that the preparation is oral solutions.
7. application of the composition described in claim 1 in preparation medicament for treatment of depression.
8. a kind of composition for treating depression as described in claim 1, which is characterized in that the composition also includes pharmacy
Upper acceptable auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910209432.6A CN109893646A (en) | 2019-03-19 | 2019-03-19 | A kind of composition for treating depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910209432.6A CN109893646A (en) | 2019-03-19 | 2019-03-19 | A kind of composition for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109893646A true CN109893646A (en) | 2019-06-18 |
Family
ID=66953362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910209432.6A Pending CN109893646A (en) | 2019-03-19 | 2019-03-19 | A kind of composition for treating depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109893646A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402570A (en) * | 2020-12-04 | 2021-02-26 | 石门县人民医院 | Pharmaceutical composition for regulating liver depression and blood deficiency caused by depression and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1682989A (en) * | 2005-02-21 | 2005-10-19 | 李有田 | Chinese medicine for treating depression |
| US20100204139A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of gonadorelin as a therapeutic agent |
| WO2011140607A1 (en) * | 2010-05-14 | 2011-11-17 | Keating Charlotte L | A method of treatment and diagnosis |
| CN105194631A (en) * | 2015-11-02 | 2015-12-30 | 仲学龙 | Traditional Chinese medicine preparation for treating depression |
-
2019
- 2019-03-19 CN CN201910209432.6A patent/CN109893646A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1682989A (en) * | 2005-02-21 | 2005-10-19 | 李有田 | Chinese medicine for treating depression |
| US20100204139A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of gonadorelin as a therapeutic agent |
| WO2011140607A1 (en) * | 2010-05-14 | 2011-11-17 | Keating Charlotte L | A method of treatment and diagnosis |
| CN105194631A (en) * | 2015-11-02 | 2015-12-30 | 仲学龙 | Traditional Chinese medicine preparation for treating depression |
Non-Patent Citations (1)
| Title |
|---|
| 喻东山: "性激素和抑郁症", 《国外医学.精神病学分册》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402570A (en) * | 2020-12-04 | 2021-02-26 | 石门县人民医院 | Pharmaceutical composition for regulating liver depression and blood deficiency caused by depression and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104367765A (en) | Traditional Chinese medicinal composition for treating depression as well as preparation method and application thereof | |
| CN102014931B (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN103386004B (en) | Application of traditional Chinese medicinal composition in preparation of anti-ageing medicines | |
| CN103432184A (en) | Application of great burdock fruit extract in drug production or foods | |
| CN104740425B (en) | A kind of pharmaceutical composition for treating rheumatic Bi syndrome and its production and use | |
| CN109893646A (en) | A kind of composition for treating depression | |
| CN105125946A (en) | Gardenia oral liquid clearing away heart fire and relieving restlessness and preparing method thereof | |
| CN102499916A (en) | Application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis | |
| CN104523925B (en) | Traditional Chinese medicinal composition and its application in defecation promotion | |
| CN101172124B (en) | Novel uses of pennycress, pharmaceutical composition containing the pennycress and preparation method thereof | |
| CN109350632A (en) | A kind of Chinese medicine composition for antipyretic-antalgic | |
| CN101411705B (en) | Pharmaceutical composition for preventing and treating atherosclerosis | |
| CN107789504A (en) | A kind of pharmaceutical composition for treating parkinsonism and its production and use | |
| CN1833687A (en) | Chinese medicinal compsns. for treating digestive ulcer and chronic gastritis, its prepn. and usage | |
| CN100551391C (en) | A kind of control diabetes medicament and preparation method and application | |
| CN102526512A (en) | Medicine for treating motor complications of Parkinson's diseases and application thereof | |
| CN110092806B (en) | Analgesic C of aconite19Diterpene alkaloid glucoside and application thereof | |
| CN111643540A (en) | Eucommia ulmoides extract for treating lumbar muscle strain and preparation method thereof | |
| CN104771451A (en) | Traditional Chinese medicine extract with antidepressant effect and application thereof | |
| CN112279811A (en) | C20Diterpenoid alkaloids, their preparation and use for treating pain related diseases | |
| CN108771683A (en) | Treat Paeoniflorin/synephrine composition and its application of gastrointestinal dysfunction or intestinal irritable syndrome | |
| CN112694441B (en) | C 20 Diterpenoid alkaloids, their preparation and use for treating pain related diseases | |
| CN102210752A (en) | Application of suspension and extract of fleece flower root or prepared fleece flower root in preparation of medicaments for treating depression | |
| CN106236825A (en) | The application in antidepressant of Millettia Speciosa and its extract and antidepressant drug | |
| CN108606996A (en) | It is a kind of that there is the pharmaceutical composition for improving immune function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190618 |
|
| WD01 | Invention patent application deemed withdrawn after publication |